TriSalus Life Sciences In... (TLSI)
TriSalus Life Sciences Statistics
Share Statistics
TriSalus Life Sciences has 30.49M shares outstanding. The number of shares has increased by 15.45% in one year.
| Shares Outstanding | 30.49M |
| Shares Change (YoY) | 15.45% |
| Shares Change (QoQ) | 4.03% |
| Owned by Institutions (%) | 8.85% |
| Shares Floating | 12.69M |
| Failed to Deliver (FTD) Shares | 171 |
| FTD / Avg. Volume | 0.38% |
Short Selling Information
The latest short interest is 58.44K, so 0.19% of the outstanding shares have been sold short.
| Short Interest | 58.44K |
| Short % of Shares Out | 0.19% |
| Short % of Float | 0.53% |
| Short Ratio (days to cover) | 2.38 |
Valuation Ratios
The PE ratio is -1.34 and the forward PE ratio is -4.95. TriSalus Life Sciences's PEG ratio is 0.
| PE Ratio | -1.34 |
| Forward PE | -4.95 |
| PS Ratio | 4.29 |
| Forward PS | 1.5 |
| PB Ratio | -3.06 |
| P/FCF Ratio | -1.55 |
| PEG Ratio | 0 |
Enterprise Valuation
TriSalus Life Sciences Inc. has an Enterprise Value (EV) of 69.21M.
| EV / Earnings | -1.17 |
| EV / Sales | 3.74 |
| EV / EBITDA | -1.19 |
| EV / EBIT | -1.28 |
| EV / FCF | -1.35 |
Financial Position
The company has a current ratio of 1.42, with a Debt / Equity ratio of -0.06.
| Current Ratio | 1.42 |
| Quick Ratio | 1.25 |
| Debt / Equity | -0.06 |
| Total Debt / Capitalization | -6.55 |
| Cash Flow / Debt | -31.38 |
| Interest Coverage | -3384.38 |
Financial Efficiency
Return on equity (ROE) is 2.28% and return on capital (ROIC) is 222.48%.
| Return on Equity (ROE) | 2.28% |
| Return on Assets (ROA) | -2.29% |
| Return on Capital (ROIC) | 222.48% |
| Revenue Per Employee | $159,577.59 |
| Profits Per Employee | $-508,948.28 |
| Employee Count | 116 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 1.02 |
Taxes
| Income Tax | 9K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -42.56% in the last 52 weeks. The beta is 0.48, so TriSalus Life Sciences's price volatility has been higher than the market average.
| Beta | 0.48 |
| 52-Week Price Change | -42.56% |
| 50-Day Moving Average | 5.39 |
| 200-Day Moving Average | 4.99 |
| Relative Strength Index (RSI) | 55.78 |
| Average Volume (20 Days) | 45.5K |
Income Statement
In the last 12 months, TriSalus Life Sciences had revenue of 18.51M and earned -59.04M in profits. Earnings per share was -6.73.
| Revenue | 18.51M |
| Gross Profit | 15.91M |
| Operating Income | -54.15M |
| Net Income | -59.04M |
| EBITDA | -58.3M |
| EBIT | -54.15M |
| Earnings Per Share (EPS) | -6.73 |
Balance Sheet
The company has 11.78M in cash and 1.59M in debt, giving a net cash position of 10.18M.
| Cash & Cash Equivalents | 11.78M |
| Total Debt | 1.59M |
| Net Cash | 10.18M |
| Retained Earnings | -248.38M |
| Total Assets | 27.48M |
| Working Capital | 13.89M |
Cash Flow
In the last 12 months, operating cash flow was -50.05M and capital expenditures -1.12M, giving a free cash flow of -51.17M.
| Operating Cash Flow | -50.05M |
| Capital Expenditures | -1.12M |
| Free Cash Flow | -51.17M |
| FCF Per Share | -5.45 |
Margins
Gross margin is 85.93%, with operating and profit margins of -292.53% and -318.93%.
| Gross Margin | 85.93% |
| Operating Margin | -292.53% |
| Pretax Margin | -318.89% |
| Profit Margin | -318.93% |
| EBITDA Margin | -314.94% |
| EBIT Margin | -292.53% |
| FCF Margin | -276.41% |
Dividends & Yields
TLSI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -120.18% |
| FCF Yield | -29.96% |
Analyst Forecast
The average price target for TLSI is $11, which is 96.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $11 |
| Price Target Difference | 96.4% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -16.44 |
| Piotroski F-Score | 2 |